Search
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalThe enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures.
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.
Gadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigationalA263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnCalcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.
GT 389-255
go.drugbank.com/drugs/DB05894ExperimentalIt is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.
Indian frankincense
go.drugbank.com/drugs/DB14275ApprovedInvestigationalIndian frankincense is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: ACTS38 BoswelliaGel (100ml)BNT-162A1
go.drugbank.com/drugs/DB16402InvestigationalBNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Artemisia tridentata pollen
go.drugbank.com/drugs/DB10390ApprovedArtemisia tridentata pollen is the pollen of the Artemisia tridentata plant. Artemisia tridentata pollen is mainly used in allergenic testing.
Mixtures: Number Four Weed MixtureCHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnagents are commonly used as first-line treatments to manage aGvHD, about 30-50% of patients with aGvHD experience inadequately control of disease with first-line therapies, putting them in a risk for poor